4//SEC Filing
Muralidhar Bali 4
Accession 0000905718-21-000744
CIK 0001637715other
Filed
Jun 1, 8:00 PM ET
Accepted
Jun 2, 10:37 AM ET
Size
6.2 KB
Accession
0000905718-21-000744
Insider Transaction Report
Form 4
Muralidhar Bali
Director
Transactions
- Purchase
Common Stock
2021-05-28$9.50/sh+14$133→ 1,865,275 total(indirect: By Abingworth Bioventures 8 LP)
Footnotes (2)
- [F1]The shares are held by Abingworth Bioventures 8 LP ("Abingworth 8"). Abingworth Bioventures 8 GP LP serves as the general partner of Abingworth 8. Abingworth General Partner 8 LLP, (together with Abingworth Bioventures 8 GP LP, the "General Partners"), serves as the general partner of Abingworth Bioventures 8 GP LP. Abingworth 8 (acting by its general partner Abingworth Bioventures 8 GP LP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP all investment and dispositive power over the securities held by Abingworth 8. The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth 8 which approves investment and voting decisions by majority vote and no individual member has the sole control or voting power over the securities held by Abingworth 8.
- [F2]Each of Abingworth 8, Abingworth LLP, the General Partners, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the common stock held by Abingworth 8, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Documents
Issuer
Reneo Pharmaceuticals, Inc.
CIK 0001637715
Entity typeother
Related Parties
1- filerCIK 0001784138
Filing Metadata
- Form type
- 4
- Filed
- Jun 1, 8:00 PM ET
- Accepted
- Jun 2, 10:37 AM ET
- Size
- 6.2 KB